Cardiol Therapeutics (TSE:CRDL) Shares Up 1.6% – Still a Buy?
by Tristan Rich · The Markets DailyCardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) shares shot up 1.6% during mid-day trading on Thursday . The stock traded as high as C$1.94 and last traded at C$1.93. Approximately 130,571 shares were traded during mid-day trading, an increase of 33% from the average session volume of 98,254 shares. The stock had previously closed at C$1.90.
Cardiol Therapeutics Trading Up 1.6%
The business has a 50 day moving average of C$1.60 and a 200-day moving average of C$1.61. The company has a current ratio of 4.39, a quick ratio of 6.84 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of C$222.47 million, a P/E ratio of -4.95 and a beta of 0.27.
Cardiol Therapeutics (TSE:CRDL – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported C($0.10) earnings per share for the quarter. Analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.